TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00450138

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZD6474 (vandetanib)
Description: once daily oral dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZD6474 (vandetanib)
Description: once daily oral dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: intravenous infusion

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation
Description: radiation of head and neck

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation
Description: radiation of head and neck
Study: NCT00422734

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: tadalafil
Description: 5 mg tadalafil tablet taken by mouth once a day for 12 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo tablet taken by mouth once a day for 12 weeks
Study: NCT02400008

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgery for bilateral laryngeal reinnervation
Description: Surgery for bilateral laryngeal reinnervation assessed for patient with bilateral vocal fold paralysis
Study: NCT01854606

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AEB071
Description: a Protein Kinase C Inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus
Description: mTOR inhibitor
Study: NCT02344342

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Telemonitoring
Description: The Health Buddy web management system allows the patient to enter self-care data through a study provided tablet computer.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Telemonitoring
Description: The Health Buddy web management system allows the patient to enter self-care data through a study provided tablet computer.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Flexible Diuretic Regimen
Description: Patients will have a prescribed diuretic regimen specified by specific weight ranges.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Flexible Diuretic Regimen
Description: Patients will have a prescribed diuretic regimen specified by specific weight ranges.
Study: NCT00557531

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BL-1040
Description: 2 mL of BL-1040
Study: NCT03375736

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: whole body vibration
Description: The children and young adults will receive the WBVT when standing still on a vibration platform of 20 Hertz and a peak-to-peak amplitude of 2 mm: sessions will be 18 minutes in length, 4 days per week for 4 weeks. Assessments will be performed at baseline and at completion of the intervention to examine the functional abilities of these children and young adults. The vibration frequency, duration and amplitude will be progressively increased over 2 weeks to the maximum of 3 minutes of 20 Hz with a peak-to-peak amplitude of 2mm.
Study: NCT04610411

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: surgical navigation
Description: surgical navigation for pedicle screw placement and rod beinding using AR-glasses and a specially developed software

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: standard surgical method
Description: standard surgical method established at the institution
Study: NCT01244165

Intervention type: DEVICE
Group type: OTHER
Intervention: Cytrix

Intervention type: OTHER
Group type: OTHER
Intervention: Other treatments for pelvic organ prolapse
Description: Treatments for pelvic organ prolapse using other products (standard of care for treatment of pelvic organ prolapse)
Study: NCT00654797

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: glucose control with computer generated recommendations
Description: Insulin dosing will be recommended by the computer tools based on subject glucose values. Bedside clinicians will have the ablity to accept or reject the suggested dose.
Study: NCT00798304

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: meningococcal B rLP2086 vaccine
Description: vaccination

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Routine age appropriate childhood vaccines
Description: vaccination

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: meningococcal B rLP2086 vaccine
Description: vaccination

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Routine age appropriate childhood vaccines
Description: vaccination

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Routine age appropriate childhood vaccines
Description: vaccination
Study: NCT00658606

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: alefacept
Description: IM

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Narrow Band UVB Phototherapy
Description: UVB Phototherapy
Study: NCT01806012

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sealing tissue with the Enseal device

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional supracervical hysterectomy
Study: NCT03573869

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cryoballoon ablation
Description: Left atrial ablation using cryoballoon to achieve pulmonary vein isolation
Study: NCT05302947

Intervention type: DRUG
Intervention: Netakimab
Description: Netakimab was administered by a single subcutaneous injection of 120 mg

Intervention type: OTHER
Intervention: Standard of care therapy
Description: SOC treatment included hydroxychloroquine (400 mg twice on day 1, followed by 200 mg twice per day on days 5-10), azithromycin (500 mg once per day for 5 days), lopinavir-ritonavir (400/100 mg twice per day for 14 days), and low molecular-weight heparin according to personal indicators
Study: NCT04617483

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Two doses of commercial scale inactivated SARS-CoV-2 vaccine at the schedule of day 0,14
Description: The antigen content of the commercial scale inactivated SARS-CoV-2 vaccine was 600SU/0.5ml, vaccinated in the age group 26-45.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Two doses of pilot scale inactivated SARS-CoV-2 vaccine at the schedule of day 0,14
Description: The antigen content of the pilot scale inactivated SARS-CoV-2 vaccine was 600SU/0.5ml, vaccinated in the age group 18-59.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Two doses of pilot scale inactivated SARS-CoV-2 vaccine at the schedule of day 0,14 in elderly
Description: The antigen content of the pilot scale inactivated SARS-CoV-2 vaccine was 600SU/0.5ml, vaccinated in the age group above 60.
Study: NCT03610321

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gefarnate
Description: Gefarnate (100 mg, three times daily, oral) treatment for 1 month.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Statin
Description: Statin treatment (atorvastatin 20 mg or rosuvastatin 10 mg, once daily, oral) for 1 month.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Statin
Description: Statin treatment (atorvastatin 20 mg or rosuvastatin 10 mg, once daily, oral) for 1 month.
Study: NCT01583283

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACY-1215
Description: Dose escalation up to 480 mg administered orally on Days 1-5, 8-12 and 15-19 of a 28 day dosing schedule.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lenalidomide
Description: Dosed on Days 1-21 of a 28 day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Dosed on Days 1, 8, 15 and 22 of a 28 day treatment cycle.
Study: NCT01905774

Intervention type: DRUG
Intervention: Deferasirox
Study: NCT03816111

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: TEACH-PD Training Curriculum
Description: The TEACH-PD training modules have been developed by a core group of renal nurses from the HOME Network in conjunction with senior medical clinicians from the Australasian Kidney Trials Network, eLearning curriculum developers, consumer representatives, and education experts, in line with the International Society for Peritoneal Dialysis guidelines, utilizing modern adult learning principles and best practice eLearning techniques.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Current standard PD training
Description: Current PD training materials and plan
Study: NCT02553798

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glycopyrronium Topical Wipes
Description: Glycopyrronium Topical Wipes
Study: NCT04041492

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Supplementation with Vitamin D3 y K2
Description: Supplementation at a dose of 1 capsule every 24 hours x 3 months

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Supplementation with Vitamin D3 y K2
Description: Supplementation at a dose of 1 capsule every 24 hours x 3 months

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Supplementation with Vitamin D3 y K2
Description: Supplementation at a dose of 1 capsule every 24 hours x 3 months
Study: NCT03264612

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Aerobic exercise
Description: Females in group I were instructed to engage into swimming exercise 30 minutes daily, 3 times weekly for 3 months. Exercise was ceased on the first 3 days of menstrual cycle then resumed afterwards.~The exercise included three stages: warming up, swimming and cooling down.
Study: NCT00983541

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluorouracil (5-FU)
Description: 5-FU Injection,USP (GeneraMedix Inc.) is effective in palliative management of carcinoma (colon, rectum, breast, stomach, pancreas) FDA approved in 1962-NDA (New Drug Application)012209. This study uses 350 mg/m2/day days 1-5 each week of radiation therapy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Brachytherapy or SBRT (Stereotactic body radiation therapy)
Description: Patients receive 45 Gy (gray) external beam radiation therapy including the primary tumor and regular lymph nodes (25 fractions over 5 weeks). Within 1 month of external beam radiation therapy, patients will have boost treatment of 20 Gy in 4 fractions, via Ir-192 brachytherapy or SBRT (Stereotactic Body Radiation Therapy).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Pancreatic:Indicated as first line treatment for patients with locally advanced (nonresectable Stage II or III) or metastatic(Stage IV) pancreatic adenocarcinoma.~Ovarian:Gemzar with carboplatin is indicated for treatment of patients with advanced ovarian cancer relapsed 6 months after plat-based therapy.~Breast:Gemzar with paclitaxel is indicated for first line treatment of patients with metastatic breast cancer after failed anthracycline-containing adjuvant chemotherapy, unless anthracyclines.~Non-small cell lung cancer(NSCLC):Gemzar is indicated with cisplatin for first line treatment of patients with inoperable, local advanced (Stage IIIA/IIIB), metastatic (Stage IV) NSCLC.
Study: NCT02741466

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Coppertone (BAY987517)
Description: Each 50 cm\*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm\*2 test application. Formulation number - SR16-01.
Study: NCT04889170

Intervention type: OTHER
Intervention: Intervention
Description: Intervention: After recording the patient characteristics and the baseline dysphagia characteristics, the intervention begins. The intervention lasts 3 weeks, by extended stay it lasts 5 or 7 weeks.~The intervention has two parts. One part of the intervention is the biofeedback therapy. The biofeedback therapy means that the patient and an SLT watch the video of the FEES together and discuss the findings. The other part of the intervention is a swallow training or a voice training. The frequency of therapy is minimum 3 times a week, the duration of one therapy is minimum 25 minutes.~Allocation to the Groups will be done by a randomization software

Intervention type: OTHER
Intervention: Intervention
Description: Intervention: After recording the patient characteristics and the baseline dysphagia characteristics, the intervention begins. The intervention lasts 3 weeks, by extended stay it lasts 5 or 7 weeks.~The intervention has two parts. One part of the intervention is the biofeedback therapy. The biofeedback therapy means that the patient and an SLT watch the video of the FEES together and discuss the findings. The other part of the intervention is a swallow training or a voice training. The frequency of therapy is minimum 3 times a week, the duration of one therapy is minimum 25 minutes.~Allocation to the Groups will be done by a randomization software
Study: NCT00695214

Intervention type: DRUG
Group type: OTHER
Intervention: Propofol sedation
Description: Patients receive an intravenous propofol infusion titrated to reach a target level of sedation, sleep with arousability to verbal stimuli.
Study: NCT02445742

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bosutinib
Description: 500 mg/day of Bosutinib during the study until disease progression, unacceptable toxicity, or withdrawal of consent occurs
Study: NCT00555776

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gabapentin
Description: Gabapentin, 600 mg bid for the first two weeks, increased to a maximum dose of 1800 mg per day during the next 6 weeks if necessary.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo is given with the same definition as Gabapentin
Study: NCT03376126

Intervention type: OTHER
Intervention: Minimal-invasive isolated limb perfusion
Description: Minimal-invasive isolated limb perfusion
Study: NCT03544281

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Belantamab mafodotin
Description: Selected doses of belantamab mafodotin will be administered as an infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Belantamab mafodotin
Description: Selected doses of belantamab mafodotin will be administered as an infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Lenalidomide will be administered as 25 or 10 mg,orally, with belantamab mafodotin and dexamethasone.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Dexamethasone will be administered as 20 or 40 mg, orally with belantamab mafodotin.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Dexamethasone will be administered as 20 or 40 mg, orally with belantamab mafodotin.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: Bortezomib will be administered as 1.3 mg/m\^2, as SC or IV, with belantamab mafodotin and dexamethasone.
Study: NCT01778751

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Home Telehealth with Behavioral Education Component
Description: The primary effectiveness outcome for this study will be hemoglobin A1c. Secondary effectiveness outcomes will include measures of diabetes self-care, self-reported medication adherence, and depressive symptoms.
Study: NCT04242485

Intervention type: OTHER
Group type: OTHER
Intervention: Osteopathic manipulative treatment
Description: Each osteopathic manipulative treatment consisted of a structured evaluation to diagnose somatic dysfunction of the pelvis, abdomen, vertebral spine, and upper and lower limbs (10 min), followed by the therapeutic application of manually guided forces to improve physiological function and homeostasis that has been altered by somatic dysfunction for 20 min, using techniques that were left at the discretion of the osteopath, including the myofascial release and cranial sacrum techniques

Intervention type: OTHER
Group type: OTHER
Intervention: Osteopathic manipulative treatment
Description: Each osteopathic manipulative treatment consisted of a structured evaluation to diagnose somatic dysfunction of the pelvis, abdomen, vertebral spine, and upper and lower limbs (10 min), followed by the therapeutic application of manually guided forces to improve physiological function and homeostasis that has been altered by somatic dysfunction for 20 min, using techniques that were left at the discretion of the osteopath, including the myofascial release and cranial sacrum techniques

Intervention type: OTHER
Group type: OTHER
Intervention: Sham treatment
Description: The sham treatment consisted only in soft touch of the same body areas involved in the osteopathic manipulative treatment protocol without applying any pressure

Intervention type: OTHER
Group type: OTHER
Intervention: Sham treatment
Description: The sham treatment consisted only in soft touch of the same body areas involved in the osteopathic manipulative treatment protocol without applying any pressure
Study: NCT00596063

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Wosulin R
Description: Penfill cartridges; Single Dose, 0.2 IU/ kg;

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Novolin R
Description: Penfill cartridges; Single Dose, 0.2 IU/ kg;
Study: NCT03642444

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Cane
Description: Assistive walking device

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Elasticated worn orthotic-garment
Description: Assistive walking device -elasticated worn orthotic garment
Study: NCT01530802

Intervention type: PROCEDURE
Group type: NO_INTERVENTION
Intervention: clipping of uterine arteries during laparoscopic myomectomy
Description: For laparoscopy standard instruments were used.For vascular clamping we used titan made YASARGIL vessel clips. The patient is put in a 20° Trendelenburg. The surgeon coagulates a 3-4 cm long segment of peritoneum over the ileopsoas muscle. Along the coagulated segment the peritoneum is opened. The surgeon identifies the ureter at its crossing over the common iliac vessels. After medializing the ureter, the pararectal space is opened and the internal iliac artery is identified and dissected till the origin of the uterine artery. The uterine artery is isolated over a distance of about 2 cm. The vascular clip is placed over the uterine artery. Yasargil Clips are applied exclusively in patients of intervention group. Myomectomy is performed in identical fashion in both groups. At the end of myomectomy the vessel clips are removed. The metroplasty is controlled for hemostasis after reopening of the uterine vessels.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: clipping of uterine arteries during laparoscopic myomectomy
Description: For laparoscopy standard instruments were used.For vascular clamping we used titan made YASARGIL vessel clips. The patient is put in a 20° Trendelenburg. The surgeon coagulates a 3-4 cm long segment of peritoneum over the ileopsoas muscle. Along the coagulated segment the peritoneum is opened. The surgeon identifies the ureter at its crossing over the common iliac vessels. After medializing the ureter, the pararectal space is opened and the internal iliac artery is identified and dissected till the origin of the uterine artery. The uterine artery is isolated over a distance of about 2 cm. The vascular clip is placed over the uterine artery. Yasargil Clips are applied exclusively in patients of intervention group. Myomectomy is performed in identical fashion in both groups. At the end of myomectomy the vessel clips are removed. The metroplasty is controlled for hemostasis after reopening of the uterine vessels.
Study: NCT03404934

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: C-REX Ring-locking Procedure
Description: The C-REX Ring-locking Procedure is a method based on adaptive anastomosis, in which intestinal ends adapt to each other after resection due to tumor, injury, or other disease.~The investigational devices comprised of two components, i.e. C-REX LapAid and C-REX DMH/DMHC
Study: NCT02838875

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Blood samples
Description: After birth - taking blood sample from the umbilical cord (arterial and venous) + blood sample from the patient.
Study: NCT03472521

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gabapentin
Description: Treatment with analgesic adjutant commonly used for post-operative pain, titrated to effect by chronic pain specialist compared to placebo titration.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo to match gabapentin
Study: NCT04476498

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Pull-PEG with Gastropexy
Description: Additionally to a conventional pull-PEG a gastropexy will be performed.
Study: NCT00624832

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Xolair
Description: Xolair (Omalizumab) dose: 2 x 450 mg, 2 x 525 mg or 2 x 600 mg; subcutaneous injection;

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Xolair
Description: Xolair (Omalizumab) dose: 2 x 450 mg, 2 x 525 mg or 2 x 600 mg; subcutaneous injection;

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Xolair
Description: Xolair (Omalizumab) dose: 2 x 450 mg, 2 x 525 mg or 2 x 600 mg; subcutaneous injection;

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo of Xolair (omalizumab), by subcutaneous injection of a solution with a concentration of 125 mg/mL in a supine position.
Study: NCT01770808

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: AquaCal
Description: AquaCal is produced by Marigot Ltd. The daily dose of 4 capsules of AquaCal provide 800mg calcium, (the EU RDA for calcium) and 74 mgs Magnesium (EU RDA 375mg). Subjects swallowed 4 capsules/day for six weeks.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: AquaPT
Description: AquaPT is produced by Marigot Ltd according to EU and FDA requirements. The daily dose of 4 capsules of AquaPT provides 720mg calcium, 200mgs green tea (polyphenols) and 50 mgs pine bark extract. Subjects swallowed 4 capsules/day for six weeks.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects swallowed 4 capsules/day for six weeks.
Study: NCT01216332

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: High-dose trivalent inactivated influenza vaccine
Description: 0.5 mL of high-dose trivalent inactivated influenza vaccine, either one dose or 2 based on whether the patient has previously received standard dose trivalent inactivated influenza vaccine.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard dose trivalent inactivated influenza vaccine
Description: 0.5 mL standard dose trivalent inactivated influenza vaccine